公司資料
Arrowhead Pharmaceuticals 股價、新聞與催化劑
- 股票代碼:
- ARWR
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
88.70 USD (+2.38%)
收盤價
最後更新: 2026年8月17日
9.98B USD
市值
股價為何變動
Following the latest company update, “People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides”, ARWR closed up 2.38% at $88.70 on Aug 17, 2026. The move occurred in the trading session associated with this company update.
公司概覽
RNA Interference Platform
Arrowhead Pharmaceuticals develops RNA interference medicines that silence disease-causing genes. Its delivery technologies support programs targeting the liver and other tissues.
REDEMPLO
REDEMPLO, or plozasiran, is an RNAi therapy targeting APOC3. It is approved in the United States to reduce triglycerides in adults with familial chylomicronemia syndrome and is under review in additional regions.
Dual-Target Cardiometabolic RNAi
ARO-DIMER-PA is a dual-functional RNAi candidate designed to silence both PCSK9 and APOC3 in a single molecule for atherosclerotic cardiovascular disease associated with mixed hyperlipidemia.
Obesity Programs
ARO-INHBE and ARO-ALK7 are RNAi candidates targeting adipose biology. Early clinical development is assessing effects on weight loss and body composition in people with obesity.
Liver-Disease and Partnered Pipeline
ARO-PNPLA3 targets a genetically defined form of liver disease and is partnered with Madrigal. Arrowhead also advances programs across pulmonary, neuromuscular and other tissues using its TRiM platform.
未來催化劑
- European Commission decision on marketing authorization for REDEMPLO in the second quarter of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。